Thermo Fisher keeps innovating to stay ahead of its rivals

Article Excerpt

Thermo Fisher continues to introduce new products as well as upgrades to its existing offerings. That’s key to it holding on to its market-leading position. THERMO FISHER SCIENTIFIC INC., $599.02, is a buy. The company (New York symbol TMO; TSINetwork Rating: Average) (www.thermofisher.com; Shares o/s: 381.7 million; Market cap: $228.7 billion; Yield: 0.3%) recently introduced the TSX Universal Series ultra-low temperature (ULT) freezer. This latest development builds on 80 years of experience. Laboratories require reliable and effective cold storage solutions for their samples to advance critical research, adequately store samples or accelerate the development of new therapies. Notably, the TSX Series ULT platform now offers medical device units for the first time to store and preserve blood and blood products at freezing temperatures between -40°C and -86°C. Strong demand for blood and cell components for transplantation and transfusion in cancer therapies is leading the market growth of laboratory freezers. Thermo Fisher is a buy. buy…